Open AccessCost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice
Author(s) -
Bruce R. Schackman,
David W. Haas,
Sanghee S Park,
X Cynthia Li,
Kenneth A. Freedberg
Publication year - 2015
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/pgs.15.142
Subject(s) - efavirenz , dosing , cyp2b6 , genotyping , human immunodeficiency virus (hiv) , medicine , therapeutic drug monitoring , pharmacology , etravirine , antiretroviral therapy , virology , viral load , pharmacokinetics , biology , genotype , cyp3a4 , genetics , cytochrome p450 , metabolism , gene
To assess the cost-effectiveness of CYP2B6 genotyping to guide efavirenz dosing for initial HIV therapy in the USA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom